Tango Therapeutics Inc Total Liabilities
Tango Therapeutics Inc total liabilities. Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has total liabilities worth $49.35 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tango Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tango Therapeutics Inc (2019–2025)
Total liabilities of Tango Therapeutics Inc from 2019 to 2025. This chart illustrates how Tango Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Tango Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tango Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alm. Brand
CO:ALMB
|
Denmark | Dkr20.05 Billion |
|
FIELMANN AG (ADR/1/5)O.N.
F:FIE1
|
Germany | €1.42 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥8.08 Billion |
|
Dorman Products Inc
NASDAQ:DORM
|
USA | $968.43 Million |
|
Predictive Discovery Ltd
AU:PDI
|
Australia | AU$6.91 Million |
|
Optics Technology Holding Co Ltd
SHE:300489
|
China | CN¥3.76 Billion |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
China | CN¥5.21 Billion |
|
MakeMyTrip Limited
NASDAQ:MMYT
|
USA | $2.14 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Tango Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Tango Therapeutics Inc.
Liquidity & Leverage Metrics
Tango Therapeutics Inc Total Liabilities Ratios Explained
Tango Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 50.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tango Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tango Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Tango Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.51 Million | -55.11% |
| 2024-12-31 | $116.97 Million | -21.73% |
| 2023-12-31 | $149.46 Million | -20.07% |
| 2022-12-31 | $186.99 Million | +20.32% |
| 2021-12-31 | $155.41 Million | -7.85% |
| 2020-12-31 | $168.65 Million | +252.39% |
| 2019-12-31 | $47.86 Million | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more